Studies in Japan were inconclusive, leading domestic regulators to hold off on approval, partly because data from animal studies showed it could lead to birth defects. The pill was once hailed as Japan’s biggest contribution to the global coronavirus fight.
One year after BridgeBio and its partners won accelerated approval for liver cancer drug Truseltiq (infigratinib), the company is pulling a planned Phase III program after its partner announced plans to permanently discontinue distribution of the drug on Wednesday.
Odyssey Therapeutics raised $168 million in a Series B financing round, which will be used to advance its portfolio of immunomodulators and oncology therapies, according to founder and CEO Gary Glick.
Relmada Therapeutics Inc’s experimental treatment for major depressive disorder failed a keenly anticipated late-stage study, sending the drug developer’s shares plunging 85% in premarket trading.
Pfizer and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants, generated a strong immune response and was well tolerated in testing on humans.
Data recently unveiled showed GSK’s respiratory syncytial virus (RSV) vaccine was 82.6% effective in a keenly watched late-stage study involving older adults.
Besides reducing the burden of participation, sponsors benefit from lower costs and faster timelines. In addition, when patients are more engaged, patient protocol compliance increases.
Nimbus Therapeutics scored a $496 million payday through a collaboration and licensing deal with pharma giant Eli Lilly for potential therapeutics for metabolic diseases, the companies announced Tuesday.
Merck & Co. Inc. opted to jointly develop and potentially sell a personalized mRNA vaccine with Moderna Inc. for a $250 million upfront payment on Wednesday, sending the vaccine maker’s shares up over 8%.
Bayer subsidiary Vividion Therapeutics and precision oncology company Tavros Therapeutics entered into a five-year collaboration agreement, valued at up to $930 million, to discover and develop four novel oncology targets.